Aandelen in “Andere Consumentenspecialiteiten”

Aandeel Datum Koers Evolutie
vlag Savaria Corp. 12/09 20,510 CAD
-0,82% 		-0,82%
vlag SILO Pharma Inc 12/09 0,655 USD
-3,78% 		-3,78%
vlag St Dupont 12/09 0,099 EUR
-0,60% 		-0,60%

Nieuws over “Andere Consumentenspecialiteiten”

12/09 · Evolution of Société BIC’s Board of Directors composition · Persbericht

12/09 · Evolution of Société BIC’s Board of Directors composition · Persbericht

4/09 · BIC: Disclosure Of Trading In Own Shares For August 2025 · Persbericht

4/09 · BIC: Disclosure of total number of voting rights and number of shares forming the capital as of August 31, 2025 · Persbericht

13/08 · MSA Safety Names Julie A. Beck Senior Vice President, Chief Financial Officer and Treasurer · Persbericht

4/08 · MSA Safety Announces Second Quarter 2025 Results · Persbericht

4/08 · BIC: Disclosure of total number of voting rights and number of shares forming the capital as of July 31, 2025 · Persbericht

4/08 · MSA Safety Declares Quarterly Dividend · Persbericht

1/08 · BIC: Disclosure Of Trading In Own Shares for July 2025 · Persbericht

1/08 · MSA Safety Releases Latest Impact Report · Persbericht

31/07 · BIC: Release and availability of the 2025 Half-Year Financial Report · Persbericht

30/07 · BIC: First Half 2025 Results · Persbericht

21/07 · MSA Safety Schedules Second Quarter 2025 Earnings Conference Call · Persbericht

8/07 · Medtronic announces appointment of MiniMed chief financial officer ahead of intended separation into standalone company · Persbericht

4/07 · BIC: Disclosure of total number of voting rights and number of shares forming the capital as of June 30, 2025 · Persbericht

4/07 · BIC: Half-Year Liquidity Contract Statement · Persbericht

2/07 · BIC: Disclosure Of Trading In Own Shares for June 2025 · Persbericht

25/06 · Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease. · Persbericht

23/06 · BIC: Evolution in BIC’s Leadership Team · Persbericht

20/06 · BIC: Remuneration of Corporate Officer · Persbericht

Mijn selecties